BACKGROUND: China has made significant progress in medical accessibility and quality over the past decades, and quality improvements in gastroenterology and digestive endoscopy have been consistent. The study aimed to describe the status quo of gastroenterology and digestive endoscopy in the Chinese mainland based on the data from the National Clinical Improvement System (NCIS) and the Hospital Quality Monitoring System (HQMS). METHODS: Data were extracted from the NCIS and the HQMS. Data analysis included general information from the Department of Gastroenterology and Endoscopy centers, management of inpatients and outpatients, and annual volume and quality indicators of digestive endoscopy. Acute pancreatitis, gastrointestinal bleeding, inflammatory bowel disease, and cirrhosis were identified as priority diseases and were subjected to detailed analysis. RESULTS: Data from 4620 and 7074 hospitals were extracted from the NCIS and HQMS, respectively. In 2023, 9.6 gastroenterologists, 6.7 endoscopists, and 37.3 gastroenterology beds per hospital nationwide were observed, achieving 19,252.4 outpatient visits, 1615.2 hospitalizations (97.0 for acute pancreatitis, 146.1 for gastrointestinal bleeding, 40.2 for inflammatory bowel disease, and 111.4 for cirrhosis), and 9432.7 digestive endoscopic procedures per hospital. Overall, the quality of practice improved significantly. The proportion of early cancer among gastrointestinal cancers increased from 11.1% in 2015 to 23.4% in 2023, and the adenoma detection rate during colonoscopy increased from 19.3% in 2019 to 26.9% in 2023. Regarding priority diseases, hospitalizations increased, and 31-day unplanned readmission rates decreased between 2019 and 2023. The median hospitalization costs and median proportion of medication costs decreased for acute pancreatitis, gastrointestinal bleeding, and cirrhosis. However, it increased for inflammatory bowel disease. CONCLUSION This report evaluates the status quo and development of gastroenterology and digestive endoscopy in the Chinese mainland, providing guidance for future quality improvements.
Humans ; China ; Gastroenterology/statistics & numerical data* ; Gastrointestinal Hemorrhage ; Endoscopy, Gastrointestinal/statistics & numerical data* ; Endoscopy, Digestive System/statistics & numerical data*

Meng-Gen-Wu-Su (mercury)-18-composition pill was firstly recorded in the book of Gan-Lu-Si-Bu with the name of Jin-18 pill . The name of Me ng-G e n-W u-Su ( mercury )-18-composition pill was firstly recorded in the book of Me ng-Y i-Jin-G ui . Its composition and dosage had always been adjusted in the later dynasties . Until the issue of the book Ne i-Me ng G u-Me ng Che ng-Y ao Biao-Zhun , the composition and dosage of Meng-Gen-Wu-Su was promulgated. In different periods, the Meng-Gen-Wu-Su consisted of 17, 18 or 19 kinds of herbs. There are at least five different types of herbs appeared in the Meng-Gen-Wu-Su-18-composition pill. But 16 kinds of medicinals such as mercury, He-Zi, Cao-Wu, Liu-Huang, Qing-Ma-Zi, Jue-Ming-Zi, Bai-Yun-Xiang, Mu-Xiang, Shi-Chang-Pu, Su-Ge-Mu-Le, Shi-Gao, Rou-Dou-Kou, Ding-Xiang, Cao-Guo, Hong-Hua, Hei-Yun-Xiang are fixed in the composition. The proportion of Meng-Gen-Wu-Su-18-composition pill is inconsistent in different periods. The significant difference of drug dosage proportion are Liu-Huang and Bai-Yun-Xiang, followed by Qing-Ma-Zi, Jue-Ming-Zi, Cao-Guo, Wen-Guan-Mu. The Meng-Gen-Wu-Su-18-composition pill and Jin-18 pill from the book of Gan-Lu-Si-Bu are same prescription with the same composition but different names. The composition and dosage proportion of Meng-Gen-Wu-Su-18-composition pill from the book of Meng-Yi-Jin-Gui and He-Li-Le Jing-Zhu Jie-Y i Nan-Jing are the same with the same prescription name .